Drug Development Program Started Based on CAP® Human Cell Line
News Mar 04, 2009
Alloksys Life Sciences BV, CEVEC Pharmaceuticals GmbH and PharmaCell BV announce the start of Theraptech, a 2.4 million Euro therapeutic protein development program subsidized under the European Trans Bio Program.
The major objective of the Theraptech project is to develop a recombinant human alkaline phosphatase (rhuAP) using the novel versatile human CAP® cell line, which has been shown to efficiently express glycosylated proteins. The rhuAP produced in CAP® cells is expected to feature improved pharmacokinetic and safety profile allowing for repeated dosing of alkaline phosphatase in chronic diseases.
Based on a the anti-inflammatory mechanism of action of alkaline phosphatase towards e.g. TNFa, IL-6 and IL-8, as shown in both pre-clinical and clinical studies in acute conditions, we propose it to be developed as a therapeutic protein in major chronic diseases such as Rheumatoid Arthritis.
The combined expertise of the members participating in the consortium covers the entire spectrum of activities needed to drive the project from molecular biology to GMP-production and recombinant product testing in preclinical and clinical trials, pushing towards a clinical phase II compliant product within the 3-year-time frame of the project.
Commenting on this unique co-operation, PharmaCell’s CEO, Maurice Horsten, commented “Combining the strengths of our companies provides us with an excellent opportunity to build on PharmaCell’s motto Humanizing Medicine® and to push this important project forward to the benefit of many patients around the world”.
Cevec’s CEO Dr Rainer Lichtenberger added: “CEVEC is excited about the strong scientific and commercial prospects of the Theraptech project. rhuAP will turn out to perfectly demonstrate the unique strengths of CEVEC’s proprietary CAP® cell expression technology, in combination with the proven capabilities of our partners “.
On the scientific importance Alloksys’ COO, Dr Ruud Brands commented, ”rhuALP, based on the proposed mechanism of action in innate immune modulation, may enable the application in a wide array of disabling chronic inflammatory conditions, thereby eliminating the potentially adverse effects of currently marketed blockbuster products.”
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Fructose Formula Poses Risk to Babies With Metabolic DisorderNews
Babies with inherited intolerance of fructose face a risk of acute liver failure if they are fed certain widely available formulas containing fructose, pediatricians and geneticists are warning. Baby formula manufacturers should remove fructose or sucrose, or explicitly label their products to allow parents to avoid those sweeteners if necessary, the doctors say.
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE